Today we are recapping exciting GU data presented at the 2026 ASCO Annual Meeting in bladder cancer, kidney cancer, and prostate cancer.
ASCO 2026 Plenary: RASolute-302
This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial.The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) m ...Show more
Send us Fan MailNinja Nerds!In this episode of the Ninja Nerd Podcast, Zach and Rob discuss Colorectal Cancer. This comprehensive discussion focuses on the clinical presentation, pathogenesis, and management of one of the most common malignancies encountered in clinical practice. ...Show more
Send us Fan MailNinja Nerds!In this episode of the Ninja Nerd Podcast, Zach and Rob discuss two high-yield, board-relevant cases highlighting the diagnosis, staging, and treatment of esophageal adenocarcinoma and intestinal-type gastric adenocarcinoma.We begin with a 56-year-old ...Show more
Send us Fan MailNinja Nerds,Welcome to the Ninja Nerd Podcast with Zach and Rob! In this episode, we discuss Lung Cancer, a leading cause of cancer-related mortality worldwide. We explore the pathophysiology, risk factors, and key differences between non-small cell lung cancer (N ...Show more
Send us Fan MailNinja Nerds!In this episode of the Ninja Nerd Podcast, Zach and Rob explore pancreatic and hepatobiliary cancers through four patient cases packed with clinical pearls.We begin with a 63-year-old man presenting with painless jaundice, pruritus, and weight loss. Za ...Show more